Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization
Rhophylac is a highly purified, plasma-derived product comprised of Rho(D) Immune Globulin (Human) for IV or IM administration. Rhophylac is primarily indicated for the prevention of hemolytic disease of the fetus and newborn (HDN), and also indicated to prevent Rho(D) sensitization after transfusion of Rh-positive blood type to Rh-negative patient.Posted: February 2004
Related articles
Rhophylac (Rh0(D) immune globulin intravenous (human)) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
